Profile data is unavailable for this security.
About the company
Pharnext SA is a France-based biopharmaceutical company. The Company is focused on discovering, developing and licensing new therapeutic solutions (Pleodrugs) and companion tests for unmet medical needs (large and niche markets) by using the Pleotherapy approach. Pharnext SA runs all its own activities, from research through to clinical development (no further than the end of Phase II trials), and then licenses the Pleodrugs to industrial partners. The Company's prime focus is on neurodegenerative diseases and metabolic diseases.
- Revenue in EUR (TTM)150.00k
- Net income in EUR-31.55m
- Incorporated2007
- Employees44.00
- LocationPharnext SCA14 rue de la RepubliqueSURESNES 92150FranceFRA
- Phone+33 141092230
- Fax+33 141092231
- Websitehttps://www.pharnext.com/fr/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharnext SCA | 150.00k | -31.55m | 60.02k | 44.00 | -- | -- | -- | 0.4001 | -26,278,830.00 | -26,278,830.00 | 171.43 | -17,532.99 | 0.0186 | -- | 0.0298 | -- | -391.03 | -128.26 | -- | -367.63 | -22.54 | -- | -21,035.67 | -4,413.23 | -- | -- | -- | -- | -99.34 | -- | -25.57 | -- | -29.58 | -- |
| Neovacs SA | 53.48k | -5.00m | 87.92k | 23.00 | 0.00 | 0.00 | -- | 1.64 | 14,869,250.00 | 14,869,250.00 | 764.00 | 364,547.30 | 0.001 | -- | 0.5561 | 2,546.67 | -9.24 | -36.05 | -10.24 | -46.06 | -917.26 | -3,215.82 | -9,344.13 | -74,596.98 | -- | -- | 0.0286 | -- | -95.08 | -- | 70.02 | -- | 3.58 | -- |
| Obseva SA | 13.75m | 7.36m | 139.38k | 15.00 | 0.02 | 0.05 | 0.0189 | 0.0101 | 0.0599 | 0.0599 | 0.1273 | 0.024 | 0.4682 | -- | 108.39 | 893,026.20 | 25.07 | -73.61 | 37.56 | -90.70 | -- | -- | 53.55 | -838.80 | -- | -- | 0.1957 | -- | -11.55 | 314.75 | 43.60 | -- | -- | -- |
| Paion AG | -100.00bn | -100.00bn | 214.78k | 64.00 | -- | -- | -- | -- | -- | -- | -- | -0.4074 | -- | -- | -- | -- | -- | -24.86 | -- | -34.32 | -- | -- | -- | -52.40 | 0.5078 | -- | 1.17 | -- | 366.42 | 41.74 | 97.34 | -- | 129.37 | -- |
Data as of May 03 2024. Currency figures normalised to Pharnext SCA's reporting currency: Euro EUR
